Article Text

PDF
OP0224 Filgotinib (GLPG0634), An Oral Jak1 Selective Inhibitor Is Effective in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: Results from A 24-Week Phase 2B Dose Ranging Study
  1. R. Westhovens1,
  2. R. Alten2,
  3. D. Pavlova3,
  4. F.E. Enriquez Sosa4,
  5. M. Mazur5,
  6. M. Greenwald6,
  7. Aa A. Van der7,
  8. F. Vanhoutte7,
  9. C. Tasset7,
  10. P. Harrison7
  1. 1Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium
  2. 2Innere Medizin II, Schlosspark-Klinik, Berlin, Germany
  3. 3Ltd M & M Centers, Carnikava, Latvia
  4. 4Clinstile, S.A. de C.V., Mexico City, Mexico
  5. 5IMSP Institul de Cardiologie, Chisinau, Moldova, Republic of
  6. 6Desert Medical Advances, Palm Desert, United States
  7. 7Galapagos NV, Mechelen, Belgium

Abstract

Background Filgotinib (GLPG0634) is a novel oral selective JAK1 inhibitor that was evaluated in a 24-week phase 2B study in combination with methotrexate (MTX) in active rheumatoid arthritis (RA) with inadequate response to MTX. The primary endpoint of proportion of patients achieving ACR20 response after 12 weeks of treatment was met.

Objectives To present the results of the 24-week analysis.

Methods Patients with active RA on stable dose of MTX were randomized 1:1:1:1:1:1:1 in a double blinded manner to receive either placebo (PBO) or one of three doses of filgotinib (50mg, 100mg or 200mg) as once (qd) or twice daily (bid) regimen for 24 weeks (DARWIN 1 study). At Week 12, patients on placebo and 50mg dose whose tender and swollen joint counts did not improve by 20% (non-responders (NR)) were reassigned to 100mg daily.

Results 594 randomized and treated patients, mean duration of RA of 7–10 years and mean DAS28(CRP) at baseline 6.0–6.2. At Week 12, statistically significant and dose dependent higher ACR20, ACR50, ACR70, DAS28(CRP) and CDAI responses versus PBO were observed in patients on filgotinib. These responses were maintained or continued to improve through 24 weeks (Table 1). Increase in filgotinib dose from Week 12 lead to improved efficacy in PBO and 50mg NR groups (at Week 24 ACR20 57% and 42% respectively). Serious Adverse Events and Treatment-Emergent Adverse Events (TEAE) were distributed over the groups including PBO: TEAE 51% PBO and 52% filgotinib groups. No opportunistic infections or cancers occurred; one death was reported. Infections occurred in 19% PBO and 25% filgotinib groups. Laboratory parameters remained stable between 12 and 24 weeks. Increase in haemoglobin was noted in patients on filgotinib.

Table 1.

Summary of the efficacy responses after 12 and 24 weeks treatment

Conclusions Significant improvement in signs and symptoms of active RA was observed after 12 weeks and sustained or increased up to Week 24 with filgotinib in combination with MTX. The safety profile was overall acceptable.

Disclosure of Interest R. Westhovens Grant/research support from: Roche, BMS, Janssen, Galapagos NV: investigator DARWIN 1, R. Alten Grant/research support from: Galapagos NV: investigator DARWIN 1, D. Pavlova Grant/research support from: Galapagos NV: investigator DARWIN 1, F. E. Enriquez Sosa Grant/research support from: Galapagos NV: investigator DARWIN 1, M. Mazur Grant/research support from: Galapagos NV: investigator DARWIN 1, M. Greenwald Grant/research support from: Galapagos NV: investigator DARWIN 1, A. Van der Aa Employee of: Galapagos NV, F. Vanhoutte Shareholder of: Galapagos NV, Employee of: Galapagos NV, C. Tasset Employee of: Galapagos NV, P. Harrison Employee of: Galapagos NV

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.